ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Engineered IL-2 Plus Calcineurin Inhibitor Synergistically Expands Regulatory T Cells Transduced with Engineered IL-2 Receptor and Facilitates Establishment of Transplantation Tolerance

T. Hirai1, P. Lin2, T. L Ramos2, K. Garcia3, R. S Negrin2

1Urology, Tokyo Women's Medical University, Tokyo, Japan, 2Blood and Marrow Transplantation, Stanford University, Stanford, CA, 3Molecular and Cellular Physiology and Structural Biology, Stanford University, Stanford, CA

Meeting: 2022 American Transplant Congress

Abstract number: 382

Keywords: Bioengineering, Bone marrow transplantation, FK506, Mice

Topic: Basic Science » Basic Science » 10 - Treg/Other Regulatory Cell/Tolerance

Session Information

Session Name: Immunoregulation and Tolerance

Session Type: Rapid Fire Oral Abstract

Date: Monday, June 6, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 6:10pm-6:20pm

Location: Hynes Room 302

*Purpose: Clinical trials for regulatory T cell (Treg) therapy in organ transplant has shown promising results. However, it is still under the debate which drugs should be used as a standard immunosuppressive regimen in combination for Treg cell therapy. Calcineurin inhibitor (CNI) is one of the most common immunosuppressants for organ transplantations, although it might negatively affect Tregs by inhibiting IL-2 production in the other conventional T cells. To replace IL-2 signals selectively in Tregs, we introduce here an engineered orthogonal IL-2 (oIL-2) cytokine / cytokine receptor (R) pair that specifically binds with each other but does not with their wild type counterparts. We previously reported that oIL-2 stimulation provides STAT5 signaling in Tregs transduced with oIL-2R and facilitates tolerance induction. We demonstrate here that the cytokine engineering approach synergistically works with CNI.

*Methods: Murine Tregs were isolated from secondary lymphoid tissues and transduced with oIL-2R through retroviral vector during ex vivo expansion. Tregs transduced with oIL-2R (oTregs) were infused into syngeneic mice together with bone marrow allograft obtained from fully MHC-mismatched donor followed by heart transplantation from the same allogenic donor (figure 1). oIL-2 and CNIs were administered for 14 days after transplantation. Peripheral blood chimerism and heart graft survival were observed after drug cessation.

*Results: oIL-2 + CNI treated mice (N = 7) showed significant increase in oTreg population in peripheral blood compared to CNI alone mice (N = 7) (14.5 ± 5.9 % v.s. 8.13 ± 4.0 %, p = 0.0262). oIL-2 administration did not increase the population of other T cell subsets. The proportion of donor blood cell chimerism was significantly higher in oIL-2 + CNI treated mice compared to that in CNI alone mice on d180 (28.9 ± 17.4 % v.s. 7.59 ± 10.4 %, p = 0.0251). No mice treated with oIL-2 + CNI showed heart allograft rejection, whereas 5 out of 7 mice with CNI alone eventually rejected the allograft (Figure 2, Log rank test, p = 0.0070).

*Conclusions: The data implies that cytokine / cytokine receptor engineering improves the effects of Treg therapy under CNI-based regimen.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Hirai T, Lin P, Ramos TL, Garcia K, Negrin RS. Engineered IL-2 Plus Calcineurin Inhibitor Synergistically Expands Regulatory T Cells Transduced with Engineered IL-2 Receptor and Facilitates Establishment of Transplantation Tolerance [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/engineered-il-2-plus-calcineurin-inhibitor-synergistically-expands-regulatory-t-cells-transduced-with-engineered-il-2-receptor-and-facilitates-establishment-of-transplantation-tolerance/. Accessed May 30, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences